Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
bluebird bio, Inc. (NASDAQ: BLUE) Financial Restatement: Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc.
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
From The Rosen Law Firm, P.A.
Via Business Wire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
From bluebird bio, Inc.
Via Business Wire
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
bluebird bio Stock Signals Potential to be a Multi-bagger
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do 
Via MarketBeat
Topics Economy
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
bluebird bio stock is ripe for a 400% institutional short squeeze
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in 
Via MarketBeat
Topics Economy
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.